Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
Amgen disappears lung disease program after phase 2 fail
Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any primary or secondary endpoints.
Gabrielle Masson
Oct 30, 2024 5:59pm
Less than a year in, BenevolentAI CEO is out—Chutes & Ladders
Oct 18, 2024 8:30am
Amgen reports first phase 3 win for $400M eczema drug
Sep 25, 2024 5:50am
Generate gains another $1B-plus Big Pharma partner in Novartis
Sep 24, 2024 6:00am
Amgen, Merck join academic clinical trial diversity partnership
Sep 16, 2024 3:10pm
Viridian eye disease phase 3 hits, advancing push to rival Amgen
Sep 10, 2024 8:10am
